Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-03-29
2011-12-27
Anderson, Rebecca (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S326000, C514S362000, C540S523000, C546S209000, C548S135000
Reexamination Certificate
active
08084448
ABSTRACT:
Compounds of the formulaare inhibitors of protein tyrosine phosphatases (PTPases) and, thus, may be employed for the treatment of conditions mediated by PTPase activity. The compounds of the present invention may also be employed as inhibitors of other enzymes characterized with a phosphotyrosine binding region such as the SH2 domain. Accordingly, the compounds of formula (I) may be employed for prevention and/or treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels, conditions that accompany type-2 diabetes, including hyperlipidemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, irritable bowel syndrome, pancreatitis, adipose cell tumors and carcinomas such as liposarcoma, dyslipidemia, and other disorders where insulin resistance is indicated. In addition, the compounds of the present invention may be employed to treat and/or prevent cancer, osteoporosis, musculoskeletal, neurodegenerative and infectious diseases, and diseases involving inflammation and the immune system.
REFERENCES:
patent: 2004/0023974 (2004-02-01), Coppola et al.
patent: 2008/0293776 (2008-11-01), Barnes et al.
patent: 2008/0293782 (2008-11-01), Barnes et al.
patent: 2010/0035942 (2010-02-01), Barnes et al.
patent: 97/40017 (1997-10-01), None
patent: 03/082841 (2003-10-01), None
patent: 2004/041799 (2004-05-01), None
patent: WO 2004/041799 (2004-05-01), None
patent: 2004/050646 (2004-06-01), None
patent: 2007/067612 (2007-06-01), None
patent: 2007/067613 (2007-06-01), None
patent: 2007/067614 (2007-06-01), None
Golub et al. Science (1999), vol. 286 531-537.
Lala et al. Cancer and Metastasis Reviews (1998), 17(1), 91-106.
Emma Black et al: “Structure-based design of protein tyrosine phosphatase-1B inhibitors” Bioorganic & Medicinal Chemistry Letters, Oxford, GB, vol. 15, No. 10, Apr. 16, 2005, pp. 2503-2507. p. 2503, left-hand column, paragraph 1; table 2; compound 9; p. 2505, right-hand column, last paragraph.
Bright S W et al: “Competitive particle concentration flourescence immunoassays for measuring antidiabetic drug levels in mouse plasma” Journal of Immunological Methods, Elsevier Science Publishers B.V. Amsterdam, NL, vol. 207, Apr. 25, 1997, pp. 23-31. Table 4; compound 12.
Barnes David
Bebernitz Gregory Raymond
Coppola Gary Mark
Kirman Louise
Kwak Young-Shin
Alexander John B.
Anderson Rebecca
Novartis AG
Shterengarts Samantha
LandOfFree
Organic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Organic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Organic compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4271695